Type V phosphodiesterase expression in cerebral arteries with vasospasm after subarachnoid hemorrhage in a canine model

References

• Edwards DH, Byrne JV, Griffith TM. The effect of chronic subarachnoid hemorrhage on basal endothelium-derived relaxing factor activity in intrathecal cerebral arteries. JNeurosurg 1992; 76: 830–837
   PubMed Web of Science ®Google Scholar
• Fujiwara 5, Kassell NF, Sasaki T, Nakagomi T, Lehman RM. Selective hemoglobin inhibition of endothelium-dependent vaso-d ilation of rabbit basilar artery. JNeurosurg 1986; 64: 445–452
   PubMed Web of Science ®Google Scholar
• Sayama T, Suzuki 5, Fukui M. Role of inducible nitric oxide synthase in the cerebral vasospasm after subarachnoid hemorrhage in rats. Neurol Res 1999; 21: 293–298
   PubMed Web of Science ®Google Scholar
• Sehba FA, Schwartz AY, Chereshnev I, Bederson JB. Acute decrease in cerebral nitric oxide levels after subarachnoid hemorrhage. JCereb Blood Flow Metab 2000; 20: 604–611
   PubMed Web of Science ®Google Scholar
• Sobey CG, Faraci FM. Subarachnoid haemorrhage: What happens to the cerebral arteries? Clin Exp Pharmacol Physiol 1998; 25: 867–876
   PubMed Web of Science ®Google Scholar
• Pluta RM, Oldfield EH, Boock RJ. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg 1997; 87: 746–751
   PubMed Web of Science ®Google Scholar
• Thomas JE, Rosenwasser RH. Reversal of severe cerebral vaso-spasm in three patients after aneurysmal subarachnoid hemor-rhage: Initial observations regarding the use of intraventricular sodium nitroprussicb in humans. Neurosurgery 1999; 44: 48–57
   PubMed Web of Science ®Google Scholar
• Wolf EW, Banerjee A, Soble-Smith J, Dohan FC Jr, White RP, Robertson JT. Reversal of cerebral vasospasm using an intrathecally administered nitric oxide donor. Neurosurg 1998; 89: 279–288
   Web of Science ®Google Scholar
• Horky LL, Pluta RM, Boock RJ, Oldfield EH. Role of ferrous iron chelator 2,2'-dipyridyl in preventing delayed vasospasm in a primate model of subarachnoid hemorrhage. JNeurosurg 1998; 88: 298-303
   Google Scholar
• Vollmer DG, Hongo K, Ogawa H, Tsukahara T, Kassell N F. A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage. Neurosurgery 1991; 28: 27–32
   PubMed Web of Science ®Google Scholar
• Tettenborn D, Dycka J. Prevention and treatment of delayed ischemic dysfunction in patients with aneurysmal subarachnoid hemorrhage. Stroke 1990; 21(Suppl): 85-89
   Google Scholar
• Firlik KS, Kaufmann AM, Firlik AD, Jungreis CA, Yonas H. Intra-arterial papaverine for the treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Surg Neurol 1999; 51: 66–74
   PubMedGoogle Scholar
• Willette RN, Shiloh AO, Sauermelch CF, Sulpizio A, Michell MP, Cieslinski LB, Torphy Ti, Ohlstein EH. Identification, characteriza-tion, and functional role of phosphodiesterase type IV in cerebral vessels: Effects of selective phosphodiesterase inhibitors. J Cereb Blood Flow Metab 1997; 17: 210–219
   PubMed Web of Science ®Google Scholar
• Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling 5, Hetman J, Beavo JA, Phillips SC. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 2000; 28: 3702–3707
   Google Scholar
• McHenry LC Jr, Jaffe ME, Kawamura J, Goldberg HI. Effect of papaverine on regional blood flow in focal vascular disease of the brain. N Engl J Med 1970; 282: 1167–1170
   PubMed Web of Science ®Google Scholar
• Kassell NF, Helm G, Simmons N, Phillips CD, Cail WS. Treatment of cerebral vasospasm with intra-arterial papaverine. J Neurosurg 1992; 77: 848–852
   PubMed Web of Science ®Google Scholar
• Marks MP, Steinberg GK, Lane B. Intra-arterial papaverine for the treatment of vasospasm. Am Neuroradiol 1993; 14: 822–826
   PubMed Web of Science ®Google Scholar
• Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculaecarneae and aortic rings in vitro. Am Cardio 11999; 83: 3C-12C
   Google Scholar
• Todo H, Ohta 5, Wang J, Ichikawa H, Ohue 5, Kumon Y, Sakaki S. Impairment in biochemical level of arterial dilative capability of a cyclic nucleotides-dependent pathway by induced vasospasm in the canine basilar artery. J Cereb Blood Flow Metab 1998; 18: 808–817
   PubMed Web of Science ®Google Scholar
• Kasuya H, Weir BK, Nakane M, Pollock is, Johns L, Marton LS, Stefansson K. Nitric oxide synthase and guanylatecyclase levels in canine basilar artery after subarachnoid hemorrhage. JNeurosurg 1995; 82: 250–255
   PubMed Web of Science ®Google Scholar
• Kim P, Sch in i VB, Sundt TM Jr, Vanhoutte PM. Reduced production of cGMP underlies the loss of endothelium-dependentrelaxations in the canine basilar artery after subarachnoid hemorrhage. Circ Res 1992; 70: 248–256
   PubMed Web of Science ®Google Scholar
• Kotera J, Fujishige K, Akatsuka H, Imai Y, Yanaka N, Omori K. Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem 1998; 273: 26982–26990
   PubMed Web of Science ®Google Scholar
• Schaller C, Raueiser B, Rohde V, Hassler W. Cerebral vasospasm after subarachnoid haemorrhage of unknown aetiology: A clinical and transcranial Doppler study. Acta Neurochir(Wien) 1996; 138: 560-568
   Google Scholar
• Kasuya H, Weir BK, White DM, Stefansson K. Mechanism of oxyhemoglobin-induced release of endothelin-1 from cultured vascular endothelial cells and smooth-muscb cells. J Neurosurg 1993; 79: 892–898
   PubMed Web of Science ®Google Scholar
• Miyagi Y, Carpenter RC, Meguro T, Parent AD, Zhang JH. Upregulation of rho A and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J Neurosurg 2000; 93: 471–476
   PubMed Web of Science ®Google Scholar
• Giuliano F, Montorsi F, Mirone V, Rossi D, Sweeney M. Switching from intracavernous prostaglandin El injections to oral sildenafil citrate in patients with erectile dysfunction: Results of a multicenter European study. The Sildenafil Multicenter Study Group. J Urol 2000; 164: 708–711
   PubMed Web of Science ®Google Scholar
• McMahon CG, Samali R, Johnson H. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. JUrol 2000; 164: 1192–1196
   Web of Science ®Google Scholar
• Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am Cardio 11999; 83: 35C-44C
   Google Scholar